Welcome to our dedicated page for Vistagen Therapeutics news (Ticker: VTGN), a resource for investors and traders seeking the latest updates and insights on Vistagen Therapeutics stock.
Vistagen Therapeutics Inc (VTGN) is a clinical-stage biopharmaceutical company pioneering neuroscience-focused treatments through innovative stem cell technology. This page provides investors and industry professionals with essential updates on the company’s progress, including press releases, clinical trial milestones, and strategic developments.
Access real-time information on VTGN’s advancements in predictive toxicology, drug metabolism screening, and neuropsychiatric therapies. Our curated news collection ensures you stay informed about regulatory submissions, partnership announcements, and financial disclosures without needing to track multiple sources.
Key updates include progress in stem cell-derived bioassay systems, FDA communications regarding therapeutic candidates, and insights into the company’s unique approach to in vitro testing. All content is verified for accuracy and relevance to support informed decision-making.
Bookmark this page for streamlined access to VTGN’s latest developments. Check back regularly for authoritative reporting on advancements in neuroscience and biotechnology that could shape the future of drug discovery.
VistaGen Therapeutics (NASDAQ: VTGN) reported its Q1 fiscal 2022 results, highlighting progress in its PALISADE Phase 3 Program for PH94B aimed at treating social anxiety disorder. The PALISADE-1 study is on track, with topline data expected by mid-2022. The company has also received FDA approval for an exploratory Phase 2A study targeting adjustment disorder with anxiety. Financially, revenue increased to $0.4 million, while net loss rose to approximately $7.7 million, reflecting higher R&D expenses of $5.6 million. Cash on hand stands at approximately $97.8 million.
VistaGen Therapeutics (NASDAQ: VTGN) announced a conference call on August 12, 2021, at 2:00 pm PT to discuss its financial results for the fiscal year 2022 first quarter, which ended June 30, 2021. CEO Shawn Singh and the management team will provide updates on the company’s developments and milestones during this period, along with future goals. The call is open to the public, and a live audio webcast will be available. Investors can also access a playback of the call after it concludes.
VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company focused on innovative medicines for anxiety and depression, will participate in the Canaccord Genuity 41st Annual Growth Conference. The event includes a fireside chat with CEO Shawn Singh on August 11 at 1:30 p.m. PT. VistaGen will also engage in one-on-one meetings throughout the conference. A live webcast of the presentation will be available on the company's website. VistaGen’s drug candidates have shown promise in clinical studies and aim to advance treatment options for CNS disorders.
VistaGen Therapeutics (NASDAQ: VTGN) appointed Maggie FitzPatrick to its Board of Directors, replacing Dr. Brian J. Underdown, who retired. FitzPatrick, a recognized corporate affairs expert, has extensive experience in healthcare marketing, previously working with companies like Johnson & Johnson and Cigna. Her public relations expertise is expected to benefit VistaGen as it progresses its CNS drug candidates. The company's focus remains on developing innovative therapies for anxiety and depression, with potential for significant market impact.
VistaGen Therapeutics (NASDAQ: VTGN) has announced its participation in the 'Updates in Neuropsych' panel at the William Blair Biotech Focus Conference 2021, scheduled for July 15, 2021, at 9:00 a.m. PT. The event aims to showcase advancements in the treatment of anxiety, depression, and other CNS disorders. VistaGen will also hold one-on-one meetings throughout the virtual conference. Interested parties can access the live webcast on the company’s website.
VistaGen Therapeutics (NASDAQ: VTGN) has appointed Mary L. Rotunno, J.D., to its Board of Directors. With over 30 years in healthcare and law, she aims to enhance the company’s strategies in mental health and wellness. Currently General Counsel at El Camino Health, Rotunno has a notable track record in governance and regulatory compliance. CEO Shawn Singh highlighted her insights as vital for VistaGen's upcoming corporate developments, specifically in advancing treatments for anxiety and depression disorders. This leadership change may strengthen VistaGen's position in the CNS market.
VistaGen Therapeutics (NASDAQ: VTGN) announced significant milestones in its corporate update and fiscal results for the year ended March 31, 2021. The company initiated the PALISADE-1 Phase 3 trial for PH94B, targeting rapid-onset treatment for social anxiety disorder (SAD), with topline data expected in mid-2022. VistaGen raised $127.5 million through partnerships and financing, enhancing its financial position. Notably, it formed a strategic agreement with EverInsight Therapeutics, securing $5 million upfront. The net loss decreased to $17.9 million, and cash reserves stood at $103.1 million as of March 31, 2021.
VistaGen Therapeutics (NASDAQ: VTGN) announced a corporate update conference call scheduled for June 29, 2021, at 2:00 PM PT. The call will disclose financial and operational results for the fiscal year ending March 31, 2021, and outline recent developments and future goals. CEO Shawn Singh will lead the call, which remains open to the public. A live audio webcast will also be accessible. This conference aims to inform shareholders and stakeholders about the company's progress in developing innovative treatments for CNS disorders.
VistaGen Therapeutics (NASDAQ: VTGN) announced its inclusion in the Russell 2000® Index effective June 28, 2021. This milestone is expected to enhance the company's visibility within the investment community, according to CEO Shawn K. Singh. The Russell 2000 Index is a widely recognized benchmark for small-cap companies, and its annual reconstitution considers approximately 4,000 U.S. stocks ranked by market capitalization. This move aims to introduce VistaGen to a broader investor audience as it advances its late-stage programs for anxiety and depression treatment.
VistaGen Therapeutics (NASDAQ: VTGN) has initiated its PALISADE-1 Phase 3 trial for PH94B, a nasal spray aimed at treating Social Anxiety Disorder (SAD). This randomized, double-blind, placebo-controlled study will assess the safety and efficacy of PH94B, which has received FDA Fast Track designation. The trial, involving 200 participants across 18 sites in the U.S., aims to confirm positive results seen in Phase 2 trials. Topline results are expected by mid-2022, with the potential to offer a rapid-acting treatment option for over 23 million Americans suffering from SAD.
FAQ
What is the current stock price of Vistagen Therapeutics (VTGN)?
What is the market cap of Vistagen Therapeutics (VTGN)?
